One-liner#

Adult/geriatric outpatient approach to memory change: separate delirium and depression/medication effects from MCI/dementia, assess safety and function, and start a targeted reversible-cause workup and follow-up plan.

Quick nav#

Red flags / send to ED#

  • Acute or fluctuating confusion with inattention (possible delirium), especially with fever, hypoxia, or dehydration
  • New focal neuro deficits, severe headache, or recent head trauma on anticoagulation (follow local protocol)
  • Unsafe living situation (wandering, leaving stove on, medication mismanagement) with no support
  • New hallucinations with severe agitation or inability to maintain basic self-care (urgent evaluation)

Key history#

  • Time course: acute (hours–days) vs subacute (weeks) vs chronic (months–years)
  • Functional impact (most important): meds, finances, driving, cooking, appointments
  • Delirium screen: fluctuating course, inattention, sleep-wake reversal; recent illness or new meds
  • Mood/sleep: depression/anxiety, grief, insomnia, OSA risk, alcohol/substance use
  • Medication review: anticholinergics, sedatives, opioids, polypharmacy
  • Neuro symptoms: gait change, falls, urinary incontinence, hallucinations
  • Collateral history from family/caregiver whenever possible
  • ADLs/IADLs baseline vs current; who is noticing the change (patient vs family)

Focused exam#

  • Vitals; orthostasis if indicated
  • Mental status: attention, orientation; brief screen (Mini-Cog for quick screen; MoCA/SLUMS for more detail per local practice)
  • Neuro exam and gait (parkinsonism, ataxia); assess hearing/vision barriers
  • Depression screen (PHQ-2/9) when appropriate
  • Medication list review at bedside (bring bottles when possible)

Differential (quick pattern recognition)#

Common/likely (outpatient)#

DiagnosisKeywords patients useKey cluesFocused exam cluesInitial next step
Mild cognitive impairment“Forgetful,” but independentObjective decline; preserved ADLsAbnormal screen; function intactReversible workup + monitor
Dementia (Alzheimer pattern)“Repeats questions,” losing functionGradual decline; impaired IADLsAbnormal screen; functional declineSafety planning + workup + longitudinal care
Depression/anxiety (“pseudodementia”)“Brain fog,” low motivationMood symptoms; variable effortDepressed affectTreat mood/sleep; reassess cognition
Medication/substance effect“Sleepy,” worse after medsAnticholinergics/sedativesNonfocal examDeprescribe/adjust
Hearing/vision impairment“Can’t follow conversations”Sensory loss drives apparent cognitionHearing/vision deficitsOptimize sensory inputs

Can’t-miss / urgent#

DiagnosisKeywords patients useKey cluesFocused exam cluesInitial next step
Delirium“Sudden confusion”Acute/fluctuating; illness/medsInattentionSame-day evaluation; treat cause
Stroke/subdural hematoma“New confusion after fall”Trauma/anticoagulation or focal signsFocal deficitsED now; imaging per protocol

Workup#

  • Targeted reversible-cause workup (verify local protocol): CBC, CMP, TSH, B12; consider A1c; consider UA only if urinary symptoms or delirium concern.
  • Brain imaging indications (CT or MRI):
    • Rapid progression (<6 months)
    • Age <65 with cognitive decline
    • Focal neurologic signs
    • Recent head trauma (especially on anticoagulation)
    • Gait disturbance + incontinence (NPH triad)
    • Atypical features (early personality change, hallucinations, motor symptoms)
  • Consider sleep apnea evaluation when strongly suspected (snoring, witnessed apneas, daytime sleepiness).
  • Consider hearing evaluation and vision correction when sensory loss contributes.

When NOT to image:

  • Typical gradual memory decline in elderly with normal neuro exam and no red flags
  • Imaging rarely changes management in classic Alzheimer’s pattern

Initial management#

  • Focus on safety and supports: medication simplification, caregiver involvement, home safety, driving counseling as appropriate.
  • Address reversible contributors: sleep, mood, hearing/vision, and medication burden.
  • Set expectation: cognition evaluation is longitudinal; schedule follow-up with collateral.
  • Build a concrete next-step plan: “labs now + screen + collateral visit” rather than “come back PRN.”
  • If recurrent falls or gait decline are prominent, consider also Gait instability / falls.

Driving assessment:

  • Driving is often the most sensitive topic; address early and document discussion
  • Consider referral for formal driving evaluation if uncertain
  • Red flags for unsafe driving: getting lost in familiar areas, new accidents/near-misses, family concerns
  • Many states require physician reporting of dementia diagnosis—verify local requirements

Management by diagnosis#

Suspected delirium#

  • Education: sudden confusion is often medical and time-sensitive.
  • Treatment: same-day evaluation; identify/treat trigger (infection, dehydration, meds, hypoxia) per local protocol.
  • Follow-up: same-day/urgent pathway.

Mild cognitive impairment / early dementia concern#

Education:

  • Early evaluation helps planning; many factors can worsen memory
  • No medications cure dementia, but some may modestly slow progression
  • Lifestyle factors (exercise, sleep, social engagement) are important

Treatment:

  • Reversible workup + medication review (bias toward deprescribing anticholinergics/sedatives)
  • Hearing/vision optimization; exercise and sleep regularity
  • Safety counseling: meds/finances/driving; caregiver involvement and community resources

Cholinesterase inhibitors (for mild-moderate Alzheimer’s dementia—specialist confirmation recommended):

DrugDoseContraindicationsMonitoringCostNotes
Donepezil5 mg QHS x 4–6 weeks, then 10 mg QHSSick sinus, bradycardia, GI bleedGI SE, bradycardia, weight$First-line; modest benefit; GI SE common initially
Rivastigmine patch4.6 mg/24h, increase to 9.5–13.3 mg/24h after 4 weeksSame as donepezilSame; skin irritation$$Patch reduces GI SE; rotate application sites
Memantine5 mg daily, titrate to 10 mg BID over 4 weeksSevere renal impairmentConfusion, dizziness$For moderate-severe dementia; can combine with donepezil

These medications provide modest symptomatic benefit; discuss realistic expectations with patient/family. Consider neurology/geriatrics referral for diagnosis confirmation before starting.

Medications to AVOID or REDUCE in cognitive impairment:

Medication classExamplesWhy avoid
AnticholinergicsDiphenhydramine, oxybutynin, TCAsWorsen cognition; Beers criteria
BenzodiazepinesLorazepam, alprazolamWorsen cognition; fall risk
Sedative-hypnoticsZolpidem, eszopicloneWorsen cognition; fall risk
OpioidsAllSedation; fall risk; constipation
First-gen antihistaminesDiphenhydramine, hydroxyzineAnticholinergic

Follow-up: 2–4 weeks to review labs/screen results and plan next steps (ideally with collateral).

  • Education: mood and sleep strongly affect attention and memory.
  • Treatment: treat mood/sleep; reduce substances; consider therapy resources; reassess cognition once improved.
  • Follow-up: 4–6 weeks.
  • Education: anticholinergics, sedatives, and alcohol can mimic dementia and increase fall risk.
  • Treatment: deprescribing plan per local protocol; simplify regimen; counsel on alcohol reduction.
  • Follow-up: 2–6 weeks depending on changes and risk.

Follow-up#

  • Reassess in 2–4 weeks to review labs, screening results, and collateral history.
  • Urgent return for sudden worsening confusion, new weakness/numbness, severe headache, or inability to stay safe at home.
  • If not improving or steadily worsening over 2–3 visits, escalate (additional cognitive testing, imaging if indicated, and referral) based on local workflow.

Patient instructions#

  • Bring a family member/caregiver to the next visit if possible and bring a medication list.
  • Prioritize sleep and regular daily routines; stay physically active as tolerated.
  • Reduce alcohol and avoid sedating/anticholinergic medications unless prescribed.
  • Seek urgent care now for sudden confusion, new weakness/numbness, severe headache, or after a head injury (especially on blood thinners).

Smartphrase snippets#

Cognitive concern, initial workup: Memory concerns reported by [patient/family]. Functional status: [independent in ADLs/IADLs vs decline in X]. Mini-Cog/MoCA score: [X]. No red flags for delirium (no acute onset, no fluctuation, no inattention). Reversible cause workup ordered: CBC, CMP, TSH, B12. Medication review performed—[no high-risk meds identified/discontinued X]. Follow up in 2–4 weeks with family member to review results. Driving safety discussed.

MCI/early dementia, management: Cognitive testing consistent with [MCI/mild dementia]. Reversible workup [negative/showed X]. Discussed diagnosis, prognosis, and safety planning with patient and [family member]. Plan: [starting donepezil 5 mg QHS/referral to neurology-memory clinic/observation]. Reviewed medications to avoid. Caregiver resources provided. Follow up [timeframe].

Delirium concern, same-day evaluation: Acute confusion with [fluctuating course/inattention/recent illness]. Concerning for delirium. Referred for same-day evaluation to identify and treat underlying cause. Family instructed on delirium precautions. If worsening or unable to be evaluated today, proceed to ED.

Complaint pages#

Problem pages#

Backward Numbness / Tingling Tremor Forward